Reference Populations
What Is a Reference Population?
A reference population is a specific, relevant group of people (e.g., general population, clinical population).
- During the development of a HealthMeasure, a large sample from the reference population was thoroughly assessed with the measure. That sample’s average score was 50.
- Thus, if a person completes a HealthMeasure today and gets a score of 50, we can say that their score is the same score as the average for the reference population.
Knowing the reference population for a measure helps you interpret a score because you know who you are being compared to.
Overview of HealthMeasures Reference Populations
For most HealthMeasures, the reference population is the general population. PROMIS® adult measures were developed with a large sample of individuals who represented the 2000 U.S. General Census (the general population). PROMIS pediatric and parent proxy “GenPop” measures were developed with a large sample of individuals who represented the 2020 U.S. General Census (the general population).
There are some exceptions that you would expect. Specifically, measures that are likely only relevant to people with certain health conditions often use a clinical sample for the reference population. For example, the PROMIS Dyspnea measures have people with Chronic Obstructive Pulmonary Disease (COPD) as the reference population. The Smoking measures use daily smokers, and the Self-Efficacy for Managing Chronic Conditions measures use a clinical sample as the reference population.
The tables below show the reference populations for PROMIS, Neuro-QoL™, ASCQ-Me®, and NIH Toolbox® measures.
HealthMeasures Reference Populations
Measure Domain | Reference Population (Centering Sample) |
|---|---|
| Ability to Participate in Social Roles and Activities (v2.0) | General population |
| Alcohol – Alcohol Use | General population + Clinical sample |
| Alcohol – Negative Consequences | General population + Clinical sample |
| Alcohol – Negative Expectancies | General population + Clinical sample |
| Alcohol – Positive Consequences | General population + Clinical sample |
| Alcohol – Positive Expectancies | General population + Clinical sample |
| Anger | General population |
| Anxiety | General population |
| Anxiety (PROMIS-Cancer) | General population |
| Cognitive Function | General population |
| Cognitive Function – Abilities | General population |
| Companionship | General population |
| Depression | General population |
| Depression (PROMIS-Cancer) | General population |
| Dyspnea – Activity Motivation | n/a – Uncalibrated item pool |
| Dyspnea – Activity Requirements | n/a – Uncalibrated item pool |
| Dyspnea – Airborne Exposure | n/a – Uncalibrated item pool |
| Dyspnea – Assistive Devices | n/a – Uncalibrated item pool |
| Dyspnea – Characteristics | n/a – Uncalibrated item pool |
| Dyspnea – Emotional Response | n/a – Uncalibrated item pool |
| Dyspnea – Functional Limitations | COPD Sample |
| Dyspnea – Severity | COPD Sample |
| Dyspnea – Task Avoidance | n/a – Uncalibrated item pool |
| Dyspnea – Time Extension | n/a – Uncalibrated item pool |
| Emotional Support | General population |
| Fatigue | General population |
| Fatigue (PROMIS-Cancer) | General population |
| Gastrointestinal – Belly Pain | General Population who reported at least 1 GI symptom |
| Gastrointestinal – Bowel Incontinence | n/a – Uncalibrated item pool |
| Gastrointestinal – Constipation | General Population who reported at least 1 GI symptom |
| Gastrointestinal – Diarrhea | General Population who reported at least 1 GI symptom |
| Gastrointestinal – Disrupted Swallowing | General Population who reported at least 1 GI symptom |
| Gastrointestinal – Gas and Bloating | General Population who reported at least 1 GI symptom |
| Gastrointestinal – Gastroesophageal Reflux | General Population who reported at least 1 GI symptom |
| Gastrointestinal – Nausea and Vomiting | General Population who reported at least 1 GI symptom |
| Global Mental | General population |
| Global Physical | General population |
| Healthcare Access Satisfaction | Clinical Sample (Type 2 Diabetes Mellitus) |
| Illness Burden | Clinical Sample (Type 2 Diabetes Mellitus) |
| Informational Support | General population |
| Instrumental Support | General population |
| Itch – Activity & Clothing | Clinical sample |
| Itch – Interference | Clinical sample |
| Itch – Mood & Sleep | Clinical sample |
| Itch – Quality | Clinical sample |
| Itch – Scratching Behavior | Clinical sample |
| Itch – Severity | Clinical sample |
| Itch – Triggers | Clinical sample |
| Life Satisfaction | General population |
| Meaning and Purpose | General population |
| Medication Adherence | n/a |
| Mobility | General population |
| Pain – Behavior | General population |
| Pain – Interference | General population |
| Pain Interference (PROMIS-Cancer) | General population |
| Pain Intensity | General population |
| Pain Quality – Neuropathic Pain | Clinical sample with painful conditions |
| Pain Quality – Nociceptive Pain | Clinical sample with painful conditions |
| Physical Function | General population |
| Physical Function (PROMIS-Cancer) | General population |
| Physical Function for Samples with Mobility Aid Users | Clinical Sample |
| Positive Affect | General population |
| Positive Attitudes Toward Complementary and Integrative Medicine | Clinical sample (population who reported receiving care from a healthcare provider) |
| Positive Outlook | Clinical sample (population who reported receiving care from a healthcare provider) |
| Positive Treatment Expectations | Clinical sample (population who reported receiving care from a healthcare provider) |
| Psychosocial Illness Impact – Negative | Clinical sample (cancer) |
| Psychosocial Illness Impact – Positive | Clinical sample (cancer) |
| Satisfaction with Participation in Discretionary Social Activities (v1.0) | General population |
| Satisfaction with Participation in Social Roles (v1.0) | General population |
| Satisfaction with Social Roles and Activities (v2.0) | General population |
| Self-Efficacy – General | General population |
| Self-Efficacy for Managing Chronic Conditions – Manage Daily Activities | Clinical sample |
| Self-Efficacy for Managing Chronic Conditions – Manage Emotions | Clinical sample |
| Self-Efficacy for Managing Chronic Conditions – Manage Meds/Treatment | Clinical sample |
| Self-Efficacy for Managing Chronic Conditions – Manage Social Interactions | Clinical sample |
| Self-Efficacy for Managing Chronic Conditions – Manage Symptoms | Clinical sample |
| Sexual Function and Satisfaction v2: Anal Discomfort with Sexual Activity (for Sexually Active People) | n/a – Uncalibrated item pool |
| Sexual Function and Satisfaction v2: Bother Regarding Sexual Function (Male and Female measures) | n/a – Uncalibrated item pool |
| Sexual Function and Satisfaction v2: Erectile Function (for Sexually Active Men) | Sexually active men |
| Sexual Function and Satisfaction v2: Factors Interfering with Sexual Satisfaction | n/a – Uncalibrated item pool |
| Sexual Function and Satisfaction v2: Interest in Sexual Activity | n/a – Uncalibrated item pool |
| Sexual Function and Satisfaction v2: Oral Discomfort with Sexual Activity (for Sexually Active People) | Sexually active adults |
| Sexual Function and Satisfaction v2: Oral Dryness with Sexual Activity (for Sexually Active People) | Sexually active adults |
| Sexual Function and Satisfaction v2: Orgasm – Ability (for Sexually Active People) | Sexually active adults |
| Sexual Function and Satisfaction v2: Orgasm – Pleasure (for Sexually Active People) | Sexually active adults |
| Sexual Function and Satisfaction v2: Satisfaction with Sex Life | Sexually active adults |
| Sexual Function and Satisfaction v2: Screeners | n/a – Uncalibrated item pool |
| Sexual Function and Satisfaction v2: Sexual Activities (Male and Female measures) | n/a – Uncalibrated item pool |
| Sexual Function and Satisfaction v2: Therapeutic Aids for Sexual Activity (Male and Female measures) | n/a – Uncalibrated item pool |
| Sexual Function and Satisfaction v2: Vaginal Discomfort with Sexual Activity (for Sexually Active Women) | Sexually active women |
| Sexual Function and Satisfaction v2: Vaginal Lubrication for Sexual Activity (for Sexually Active Women) | Sexually active women |
| Sexual Function and Satisfaction v2: Vulvar Discomfort with Sexual Activity – Clitoral (for Sexually Active Women) | Sexually active women |
| Sexual Function and Satisfaction v2: Vulvar Discomfort with Sexual Activity – Labial (for Sexually Active Women) | Sexually active women |
| Sleep Disturbance | General population + Clinical sample |
| Sleep-Related Impairment | General population + Clinical sample |
| Smoking – Coping Expectancies | Daily smokers |
| Smoking – Emotional/Sensory Expectancies | Daily smokers |
| Smoking – Negative Health Expectancies | Daily smokers |
| Smoking – Negative Psychosocial Expectancies | Daily smokers |
| Smoking – Nicotine Dependence | Daily smokers |
| Smoking – Social Motivations | Daily smokers |
| Social Isolation | General population |
| Spirituality | Clinical sample (population who reported receiving care from a healthcare provider) |
| Substance Use – Appeal | Clinical and non-clinical substance users |
| Substance Use – Prescription Pain Medication Misuse | Participants who reported possession of a prescription for pain medication and potential misuse of such a medication |
| Substance Use – Severity | Clinical and non-clinical substance users |
| Upper Extremity | General population |
Measure Domain | Reference Population (Centering Sample) |
|---|---|
| Anger (v3.0) | General population |
| Anxiety (v3.0) | General population |
| Asthma Impact | Clinical sample |
| Cognitive Function | General population |
| Depression (v3.0) | General population |
| Family Relationships | General population |
| Fatigue (v3.0) | General population |
| Global Health | General population |
| Itch (PIQ-C) | General population |
| Life Satisfaction | General population |
| Meaning and Purpose | General population |
| Mobility (v3.0) | General population |
| Pain – Behavior (v3.0) | General population |
| Pain – Interference (v3.0) | General population |
| Pain Quality – Affective (v3.0) | General population |
| Pain Quality – Sensory (v3.0) | General population |
| Pain Quality (v3.0) | General population |
| Peer Relationships (v3.0) | General population |
| Physical Activity | General population |
| Physical Stress Experience | General population |
| Positive Affect | General population |
| Psychological Stress Experiences | General population |
| Sleep Disturbance | General population |
| Sleep-Related Impairment | General population |
| Stigma | Clinical sample (Children with chronic conditions) |
| Stigma – Skin | Clinical sample (Children with chronic conditions) |
| Strength Impact | General population |
| Upper Extremity (v3.0) | General population |
Measure Domain | Reference Population (Centering Sample) |
|---|---|
| Anger/Irritability | General population |
| Anxiety | General population |
| Depressive Symptoms | General population |
| Engagement – Curiosity | General population |
| Engagement – Persistence | General population |
| Global Health | General population |
| Physical Activity | General population |
| Positive Affect | General population |
| Self-Regulation – Flexibility | General population |
| Self-Regulation – Frustration Tolerance | General population |
| Sleep Health | General population |
| Social Relationships (Child-Caregiver, Family, Peer) | General population |
Measure Domain | Reference Population (Centering Sample) |
|---|---|
| Anger (v3.0) | General population |
| Anxiety (v3.0) | General population |
| Asthma Impact | Clinical sample |
| Cognitive Function | General population |
| Depression (v3.0) | General population |
| Family Relationships | General population |
| Fatigue (v3.0) | General population |
| Global Health | General population |
| Itch | General population |
| Life Satisfaction | General population |
| Meaning and Purpose | General population |
| Mobility (v3.0) | General population |
| Pain – Behavior (v3.0) | General population |
| Pain – Interference (v3.0) | General population |
| Peer Relationships (v3.0) | General population |
| Physical Activity | General population |
| Physical Stress Experience | General population |
| Positive Affect | General population |
| Psychological Stress Experiences | General population |
| Sleep Disturbance | General population |
| Sleep-Related Impairment | General population |
| Stigma | Clinical sample (Parents of children with chronic conditions) |
| Stigma – Skin | Clinical sample (Parents of children with chronic conditions) |
| Strength Impact | General population |
| Upper Extremity (v3.0) | General population |
Measure Domain | Reference Population (Centering Sample) |
|---|---|
| Ability to Participate in Social Roles and Activities | General population |
| Anxiety | General population |
| Cognitive Function | General population* |
| Depression | General population |
| Emotional and Behavioral Dyscontrol | General population |
| Fatigue | General population |
| Low Blood Pressure Impact on HRQOL | Clinical sample (Spinal Cord Injury) |
| Lower Extremity Function–Mobility | General population |
| Medication Adherence | Clinical sample (Type 2 Diabetes Mellitus) |
| Positive Affect and Well-Being | General population |
| Satisfaction with Social Roles and Activities | General population |
| Sleep Disturbance | General population |
| Stigma | General population |
| Upper Extremity Function–Fine Motor, ADL | General population |
*Cognition item bank was calibrated using clinical sample. It was then linked to the PROMIS (general population) and the published parameters are general population based.
Measure Domain | Reference Population (Centering Sample) |
|---|---|
| Anger | General population |
| Anxiety | General population |
| Cognitive Function | General population |
| Depression | General population |
| Fatigue | General population |
| Pain | Clinical sample |
| Social Relations – Interaction with Adults | General population |
| Social Relations – Interaction with Peers | General population |
| Stigma | Clinical sample |
| Most All ASCQ-Me measures except for the Sickle Cell Disease Medical History Checklist use people with sickle cell disease as the reference population. The measures were developed with a diverse sample of people with sickle cell disease recruited from seven clinics throughout the U.S. Respondents were any gender, varied in age from 18 to 65+, and varied in sickle cell type. Nearly one in five participants were 45 years old or older. 64% of respondents were women. Consistent with the population of patients affected, most respondents were diagnosed with sickle cell anemia (hemoglobin SS), followed by hemoglobin SC and other variants. |
| All NIH Toolbox measures for adult, pediatric, and parent report respondents use the U.S. general population as the reference population. |
T-scores
- A T-score is a standardized score, like z-scores and IQ scores. All standardized scores have a “middle” score; it is zero for z-scores, 100 for IQ scores, and 50 for T-scores.
- All T-scores have a mean of 50 and standard deviation of 10. This middle score is the mean of a large sample (i.e., the centering sample) that is representative of a relevant population (i.e., the reference population).
Reference Populations Help You Interpret Scores
When you know that a T-score of 50 is the mean for a specific population, it is easier to interpret a score quickly. You can compare someone with a HealthMeasure score to other people.
For example, if a person has a PROMIS Fatigue score of 60, we know that they are one standard deviation worse than the general population in terms of fatigue. That is because the reference population for PROMIS Fatigue is the general population. If a person has a PROMIS Nicotine Dependence score of 60, we know that they are one standard deviation worse (more dependent) than daily smokers because the reference population is daily smokers.
Deriving T-Scores
During measure development, T-scores are derived through multiple steps:
- Measures are administered to a large representative sample (the centering sample) that represents the reference population.
- Item response theory (IRT) is used to analyze the responses and create initial scores that estimate each respondent’s level of the measured domain.
- These initial scores are then transformed to the T-score metric using a linear transformation that sets the reference population’s average to 50 and standard deviation to 10.
- This transformation ensures that T-scores have a consistent meaning; a score of 50 always represents the average for the reference population.
- Once this process is complete, the measure can generate T-scores for any individual. Those T-scores are directly comparable to the reference population.
Other Comparison Groups
| Subgroup norms divide a relevant population into smaller groups to aid in interpreting scores. For example, if a person’s PROMIS Fatigue score is 60, we know that they are not just feeling tired; their fatigue is one standard deviation worse than the general population. But, you may want to know how their fatigue compares to other people their age. This is a subgroup norm: what is the mean (average) Fatigue score for people that age?
The initial norming sample for PROMIS was quite large and it was feasible to disaggregate by gender and age ranges in order to estimate subgroup norms. This was done in 2011 for comparing fatigue (Cook et al., 2011) and pain (Molton et al., 2014) by age range in the general population to that of samples of individuals with disabilities. Additionally, the gender and age range norms were calculated for PROMIS measures developed in the first phase of PROMIS testing. These were never published but are provided below for users who are interested. Means, standard deviations, and frequencies by domain are reported in the tables below. WARNING The original PROMIS norming sample was not powered to develop subgroup norms. The user should pay particular attention to the size and characteristics of the sample used to develop each subgroup norm. For example, much larger samples were used to calculate subgroup norms for males and females than for the age ranges. More confidence is warranted for subgroup norms estimated with larger sample sizes. Nevertheless, these subgroup norms can be useful both in comparing samples and interpreting scores. |
Domain | Gender | Age (Yrs) | |||||||
|---|---|---|---|---|---|---|---|---|---|
Female | Male | 18-34 | 35-44 | 45-54 | 55-64 | 65-74 | 75+ | ||
| Anger | N | 1865 | 1204 | 730 | 565 | 499 | 495 | 401 | 379 |
| Mean | 50.6 | 49.1 | 53.0 | 51.5 | 50.4 | 48.8 | 47.5 | 45.7 | |
| SD | 10.2 | 9.6 | 10.7 | 10.3 | 9.5 | 9.7 | 8.7 | 7.9 | |
| Anxiety | N | 1654 | 1069 | 659 | 496 | 417 | 442 | 365 | 345 |
| Mean | 50.9 | 48.6 | 52.4 | 50.9 | 50.1 | 49.3 | 48.1 | 46.9 | |
| SD | 10.2 | 9.5 | 10.7 | 11.1 | 9.5 | 9.5 | 8.8 | 7.9 | |
| Depression | N | 1269 | 890 | 496 | 366 | 359 | 373 | 290 | 276 |
| Mean | 50.9 | 48.7 | 52.3 | 50.6 | 50.8 | 49.5 | 48.4 | 46.5 | |
| SD | 10.1 | 9.7 | 10.9 | 10.9 | 10 | 9.7 | 8.8 | 7.2 | |
| Fatigue | N | 1884 | 1183 | 706 | 551 | 513 | 516 | 396 | 385 |
| Mean | 51.1 | 48.2 | 50.5 | 51.0 | 51.6 | 49.7 | 48.1 | 48.0 | |
| SD | 10.1 | 9.6 | 9.7 | 10.7 | 10.1 | 10.8 | 9.3 | 8.3 | |
| Pain Behavior | N | 1851 | 1199 | 699 | 561 | 507 | 507 | 402 | 374 |
| Mean | 50.7 | 49.0 | 47.6 | 50.0 | 52.2 | 51.3 | 50.1 | 49.7 | |
| SD | 10.1 | 9.7 | 10.2 | 10.6 | 10.1 | 9.7 | 9.3 | 8.7 | |
| Pain Interference | N | 1856 | 1180 | 712 | 548 | 499 | 488 | 406 | 383 |
| Mean | 51.1 | 48.3 | 47.8 | 50.1 | 51.9 | 51.6 | 49.9 | 49.7 | |
| SD | 10.3 | 9.3 | 9.0 | 10.2 | 11.1 | 10.9 | 9.3 | 8.7 | |
| Physical Function | N | 2044 | 1363 | 782 | 605 | 567 | 565 | 457 | 431 |
| Mean | 48.9 | 51.7 | 55.1 | 52.0 | 49.0 | 47.5 | 47.2 | 45.6 | |
| SD | 10.0 | 9.7 | 8.4 | 9.8 | 10.4 | 10.4 | 9.0 | 8.5 | |
| Global Mental Health | N | 3008 | 2206 | 1183 | 863 | 902 | 873 | 715 | 679 |
| Mean | 10.0 | 9.7 | 8.4 | 9.8 | 10.4 | 10.4 | 9.0 | 8.5 | |
| SD | 49.4 | 50.8 | 48.5 | 48.4 | 48.2 | 50.3 | 53.1 | 53.4 | |
| Global Physical Health | N | 3015 | 2212 | 1182 | 865 | 910 | 875 | 713 | 683 |
| Mean | 49.1 | 51.2 | 51.6 | 50.1 | 48.2 | 48.8 | 51.0 | 49.9 | |
| SD | 10.1 | 9.8 | 8.4 | 9.8 | 10.9 | 11.3 | 9.9 | 9.2 |
| Reference values are points of reference from which to understand a given single score. For example, Jensen et al. (2017) published reference values for eight PROMIS domains for individuals with cancer. They found, for instance, the mean Pain Interference score for people with cancer was 52. The reference values in their manuscript can be used to help interpret scores from other people with cancer. |
Last updated: September 29, 2026